http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 17 Jun 2026 07:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/NexTel+Medical+Outlines+its+Revenue+Model+Using+the+Innovation+of+Tomorrow%3A+Synergy+of+Advanced+Medical+Technologies+and+Massive+Sales+Infrastructure+Primed+to+Drive+Exponential+Growth/26656669.html <p>BOCA RATON, Fla., June 17, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCID: MAJI) today announced a strategic pivot, evolutionary restructuring, and operational alignment designed to transition the company from a traditional development-stage biotech entity into a fully integrated, high-revenue healthcare platform. By seamlessly uniting its pioneering scientific innovations, recurring-revenue telehealth segments, and a massive, pre-existing patient distribution outlet, NexTel is positioning itself to rapidly commercialize next-generation medical solutions and maximize shareholder value.</p> <p>At the center of this unified ecosystem are the company’s three primary operational drivers: Chairman of the Advisory Board Dr. http://www.streetinsider.com/Press+Releases/NexTel+Medical+Outlines+its+Revenue+Model+Using+the+Innovation+of+Tomorrow%3A+Synergy+of+Advanced+Medical+Technologies+and+Massive+Sales+Infrastructure+Primed+to+Drive+Exponential+Growth/26656669.html Wed, 17 Jun 2026 07:00:00 -0400 MAJI O.09748628 http://www.streetinsider.com/Press+Releases/NexTel+Medical+Outlines+its+Revenue+Model+Using+the+Innovation+of+Tomorrow%3A+Synergy+of+Advanced+Medical+Technologies+and+Massive+Sales+Infrastructure+Primed+to+Drive+Exponential+Growth/26656669.html <p>BOCA RATON, Fla., June 17, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCID: MAJI) today announced a strategic pivot, evolutionary restructuring, and operational alignment designed to transition the company from a traditional development-stage biotech entity into a fully integrated, high-revenue healthcare platform. By seamlessly uniting its pioneering scientific innovations, recurring-revenue telehealth segments, and a massive, pre-existing patient distribution outlet, NexTel is positioning itself to rapidly commercialize next-generation medical solutions and maximize shareholder value.</p> <p>At the center of this unified ecosystem are the company’s three primary operational drivers: Chairman of the Advisory Board Dr. http://www.streetinsider.com/Press+Releases/NexTel+Medical+Outlines+its+Revenue+Model+Using+the+Innovation+of+Tomorrow%3A+Synergy+of+Advanced+Medical+Technologies+and+Massive+Sales+Infrastructure+Primed+to+Drive+Exponential+Growth/26656669.html Wed, 17 Jun 2026 07:00:00 -0400 MAJI O.09748628 http://www.streetinsider.com/Globe+Newswire/NexTel+Medical+Outlines+its+Revenue+Model+Using+the+Innovation+of+Tomorrow%3A+Synergy+of+Advanced+Medical+Technologies+and+Massive+Sales+Infrastructure+Primed+to+Drive+Exponential+Growth/26656669.html <p>BOCA RATON, Fla., June 17, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCID: MAJI) today announced a strategic pivot, evolutionary restructuring, and operational alignment designed to transition the company from a traditional development-stage biotech entity into a fully integrated, high-revenue healthcare platform. By seamlessly uniting its pioneering scientific innovations, recurring-revenue telehealth segments, and a massive, pre-existing patient distribution outlet, NexTel is positioning itself to rapidly commercialize next-generation medical solutions and maximize shareholder value.</p> <p>At the center of this unified ecosystem are the company’s three primary operational drivers: Chairman of the Advisory Board Dr. http://www.streetinsider.com/Globe+Newswire/NexTel+Medical+Outlines+its+Revenue+Model+Using+the+Innovation+of+Tomorrow%3A+Synergy+of+Advanced+Medical+Technologies+and+Massive+Sales+Infrastructure+Primed+to+Drive+Exponential+Growth/26656669.html Wed, 17 Jun 2026 07:00:00 -0400 MAJI O.09748628 http://www.streetinsider.com/Globe+Newswire/NexTel+Medical+Outlines+its+Revenue+Model+Using+the+Innovation+of+Tomorrow%3A+Synergy+of+Advanced+Medical+Technologies+and+Massive+Sales+Infrastructure+Primed+to+Drive+Exponential+Growth/26656669.html <p>BOCA RATON, Fla., June 17, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCID: MAJI) today announced a strategic pivot, evolutionary restructuring, and operational alignment designed to transition the company from a traditional development-stage biotech entity into a fully integrated, high-revenue healthcare platform. By seamlessly uniting its pioneering scientific innovations, recurring-revenue telehealth segments, and a massive, pre-existing patient distribution outlet, NexTel is positioning itself to rapidly commercialize next-generation medical solutions and maximize shareholder value.</p> <p>At the center of this unified ecosystem are the company’s three primary operational drivers: Chairman of the Advisory Board Dr. http://www.streetinsider.com/Globe+Newswire/NexTel+Medical+Outlines+its+Revenue+Model+Using+the+Innovation+of+Tomorrow%3A+Synergy+of+Advanced+Medical+Technologies+and+Massive+Sales+Infrastructure+Primed+to+Drive+Exponential+Growth/26656669.html Wed, 17 Jun 2026 07:00:00 -0400 MAJI O.09748628 http://www.streetinsider.com/Press+Releases/NexTel+Medical+Corp.+Announces+Groundbreaking%2C+First-of-Its-Kind+Exosome+Characterization+Study+with+Penn+State+University/26620039.html <p><em>Led by Scientific Advisory Board Members Dr. John Bitzer and Dr. Marvin Hausman, the Study Utilizes Advanced Mass Spectrometry to Identify the Precise Bioactive Healing Compounds Within Proprietary Mushroom Exosomes, Driving New Patent Filings and Product Pipelines.</em></p> <p>ORLANDO, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCID: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems and integrated telehealth solutions, today announced a historic, first-of-its-kind analytical study in collaboration with Pennsylvania State University and esteemed Scientific Advisory Board (SAB) member, Dr. John Bitzer.</p> <p>The pioneering study utilizes state-of-the-art http://www.streetinsider.com/Press+Releases/NexTel+Medical+Corp.+Announces+Groundbreaking%2C+First-of-Its-Kind+Exosome+Characterization+Study+with+Penn+State+University/26620039.html Tue, 09 Jun 2026 07:00:00 -0400 A.24873657 MAJI O.09748628 O.13746533 http://www.streetinsider.com/Press+Releases/NexTel+Medical+Corp.+Announces+Groundbreaking%2C+First-of-Its-Kind+Exosome+Characterization+Study+with+Penn+State+University/26620039.html <p><em>Led by Scientific Advisory Board Members Dr. John Bitzer and Dr. Marvin Hausman, the Study Utilizes Advanced Mass Spectrometry to Identify the Precise Bioactive Healing Compounds Within Proprietary Mushroom Exosomes, Driving New Patent Filings and Product Pipelines.</em></p> <p>ORLANDO, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCID: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems and integrated telehealth solutions, today announced a historic, first-of-its-kind analytical study in collaboration with Pennsylvania State University and esteemed Scientific Advisory Board (SAB) member, Dr. John Bitzer.</p> <p>The pioneering study utilizes state-of-the-art http://www.streetinsider.com/Press+Releases/NexTel+Medical+Corp.+Announces+Groundbreaking%2C+First-of-Its-Kind+Exosome+Characterization+Study+with+Penn+State+University/26620039.html Tue, 09 Jun 2026 07:00:00 -0400 A.24873657 MAJI O.09748628 O.13746533 http://www.streetinsider.com/Press+Releases/NexTel+Medical+Corp.+Announces+Groundbreaking%2C+First-of-Its-Kind+Exosome+Characterization+Study+with+Penn+State+University/26620039.html <p><em>Led by Scientific Advisory Board Members Dr. John Bitzer and Dr. Marvin Hausman, the Study Utilizes Advanced Mass Spectrometry to Identify the Precise Bioactive Healing Compounds Within Proprietary Mushroom Exosomes, Driving New Patent Filings and Product Pipelines.</em></p> <p>ORLANDO, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCID: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems and integrated telehealth solutions, today announced a historic, first-of-its-kind analytical study in collaboration with Pennsylvania State University and esteemed Scientific Advisory Board (SAB) member, Dr. John Bitzer.</p> <p>The pioneering study utilizes state-of-the-art http://www.streetinsider.com/Press+Releases/NexTel+Medical+Corp.+Announces+Groundbreaking%2C+First-of-Its-Kind+Exosome+Characterization+Study+with+Penn+State+University/26620039.html Tue, 09 Jun 2026 07:00:00 -0400 A.24873657 MAJI O.09748628 O.13746533 http://www.streetinsider.com/Press+Releases/NexTel+Medical+Corp.+Announces+Groundbreaking%2C+First-of-Its-Kind+Exosome+Characterization+Study+with+Penn+State+University/26620039.html <p><em>Led by Scientific Advisory Board Members Dr. John Bitzer and Dr. Marvin Hausman, the Study Utilizes Advanced Mass Spectrometry to Identify the Precise Bioactive Healing Compounds Within Proprietary Mushroom Exosomes, Driving New Patent Filings and Product Pipelines.</em></p> <p>ORLANDO, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCID: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems and integrated telehealth solutions, today announced a historic, first-of-its-kind analytical study in collaboration with Pennsylvania State University and esteemed Scientific Advisory Board (SAB) member, Dr. John Bitzer.</p> <p>The pioneering study utilizes state-of-the-art http://www.streetinsider.com/Press+Releases/NexTel+Medical+Corp.+Announces+Groundbreaking%2C+First-of-Its-Kind+Exosome+Characterization+Study+with+Penn+State+University/26620039.html Tue, 09 Jun 2026 07:00:00 -0400 A.24873657 MAJI O.09748628 O.13746533 http://www.streetinsider.com/Globe+Newswire/NexTel+Medical+Corp.+Announces+Groundbreaking%2C+First-of-Its-Kind+Exosome+Characterization+Study+with+Penn+State+University/26620039.html <p><em>Led by Scientific Advisory Board Members Dr. John Bitzer and Dr. Marvin Hausman, the Study Utilizes Advanced Mass Spectrometry to Identify the Precise Bioactive Healing Compounds Within Proprietary Mushroom Exosomes, Driving New Patent Filings and Product Pipelines.</em></p> <p>ORLANDO, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCID: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems and integrated telehealth solutions, today announced a historic, first-of-its-kind analytical study in collaboration with Pennsylvania State University and esteemed Scientific Advisory Board (SAB) member, Dr. John Bitzer.</p> <p>The pioneering study utilizes state-of-the-art http://www.streetinsider.com/Globe+Newswire/NexTel+Medical+Corp.+Announces+Groundbreaking%2C+First-of-Its-Kind+Exosome+Characterization+Study+with+Penn+State+University/26620039.html Tue, 09 Jun 2026 07:00:00 -0400 A.24873657 MAJI O.09748628 O.13746533 http://www.streetinsider.com/Globe+Newswire/NexTel+Medical+Corp.+Announces+Groundbreaking%2C+First-of-Its-Kind+Exosome+Characterization+Study+with+Penn+State+University/26620039.html <p><em>Led by Scientific Advisory Board Members Dr. John Bitzer and Dr. Marvin Hausman, the Study Utilizes Advanced Mass Spectrometry to Identify the Precise Bioactive Healing Compounds Within Proprietary Mushroom Exosomes, Driving New Patent Filings and Product Pipelines.</em></p> <p>ORLANDO, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCID: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems and integrated telehealth solutions, today announced a historic, first-of-its-kind analytical study in collaboration with Pennsylvania State University and esteemed Scientific Advisory Board (SAB) member, Dr. John Bitzer.</p> <p>The pioneering study utilizes state-of-the-art http://www.streetinsider.com/Globe+Newswire/NexTel+Medical+Corp.+Announces+Groundbreaking%2C+First-of-Its-Kind+Exosome+Characterization+Study+with+Penn+State+University/26620039.html Tue, 09 Jun 2026 07:00:00 -0400 A.24873657 MAJI O.09748628 O.13746533 http://www.streetinsider.com/Globe+Newswire/NexTel+Medical+Corp.+Announces+Groundbreaking%2C+First-of-Its-Kind+Exosome+Characterization+Study+with+Penn+State+University/26620039.html <p><em>Led by Scientific Advisory Board Members Dr. John Bitzer and Dr. Marvin Hausman, the Study Utilizes Advanced Mass Spectrometry to Identify the Precise Bioactive Healing Compounds Within Proprietary Mushroom Exosomes, Driving New Patent Filings and Product Pipelines.</em></p> <p>ORLANDO, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCID: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems and integrated telehealth solutions, today announced a historic, first-of-its-kind analytical study in collaboration with Pennsylvania State University and esteemed Scientific Advisory Board (SAB) member, Dr. John Bitzer.</p> <p>The pioneering study utilizes state-of-the-art http://www.streetinsider.com/Globe+Newswire/NexTel+Medical+Corp.+Announces+Groundbreaking%2C+First-of-Its-Kind+Exosome+Characterization+Study+with+Penn+State+University/26620039.html Tue, 09 Jun 2026 07:00:00 -0400 A.24873657 MAJI O.09748628 O.13746533 http://www.streetinsider.com/Globe+Newswire/NexTel+Medical+Corp.+Announces+Groundbreaking%2C+First-of-Its-Kind+Exosome+Characterization+Study+with+Penn+State+University/26620039.html <p><em>Led by Scientific Advisory Board Members Dr. John Bitzer and Dr. Marvin Hausman, the Study Utilizes Advanced Mass Spectrometry to Identify the Precise Bioactive Healing Compounds Within Proprietary Mushroom Exosomes, Driving New Patent Filings and Product Pipelines.</em></p> <p>ORLANDO, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCID: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems and integrated telehealth solutions, today announced a historic, first-of-its-kind analytical study in collaboration with Pennsylvania State University and esteemed Scientific Advisory Board (SAB) member, Dr. John Bitzer.</p> <p>The pioneering study utilizes state-of-the-art http://www.streetinsider.com/Globe+Newswire/NexTel+Medical+Corp.+Announces+Groundbreaking%2C+First-of-Its-Kind+Exosome+Characterization+Study+with+Penn+State+University/26620039.html Tue, 09 Jun 2026 07:00:00 -0400 A.24873657 MAJI O.09748628 O.13746533 http://www.streetinsider.com/Mergers+and+Acquisitions/NexTel+Medical+signs+%248+million+deal+to+acquire+two+telehealth+firms/26589764.html <p>NexTel Medical Corp. (OTCPK: MAJI) announced it has executed purchase agreements to acquire JumpstartRx and NueVistraMed for $8 million, consisting of $2 million in cash and $6 million in preferred stock.</p> <p>The acquisitions bring $135,000 in monthly recurring revenue to the biotechnology company, which specializes in exosome-based delivery systems. The transaction includes a $1 million performance-based bonus tied to revenue projections and claw-back provisions if operational benchmarks are not met.</p> <p>NexTel plans to fund the cash portion using proceeds from its LMMY shares, avoiding dilution for existing shareholders. The deal is expected to close within 60 to 75 days, pending delivery of http://www.streetinsider.com/Mergers+and+Acquisitions/NexTel+Medical+signs+%248+million+deal+to+acquire+two+telehealth+firms/26589764.html Tue, 02 Jun 2026 11:24:14 -0400 MAJI O.09748628 http://www.streetinsider.com/Mergers+and+Acquisitions/NexTel+Medical+signs+%248+million+deal+to+acquire+two+telehealth+firms/26589764.html <p>NexTel Medical Corp. (OTCPK: MAJI) announced it has executed purchase agreements to acquire JumpstartRx and NueVistraMed for $8 million, consisting of $2 million in cash and $6 million in preferred stock.</p> <p>The acquisitions bring $135,000 in monthly recurring revenue to the biotechnology company, which specializes in exosome-based delivery systems. The transaction includes a $1 million performance-based bonus tied to revenue projections and claw-back provisions if operational benchmarks are not met.</p> <p>NexTel plans to fund the cash portion using proceeds from its LMMY shares, avoiding dilution for existing shareholders. The deal is expected to close within 60 to 75 days, pending delivery of http://www.streetinsider.com/Mergers+and+Acquisitions/NexTel+Medical+signs+%248+million+deal+to+acquire+two+telehealth+firms/26589764.html Tue, 02 Jun 2026 11:24:14 -0400 MAJI O.09748628 http://www.streetinsider.com/Press+Releases/NexTel+Medical+Corp.+Executes+Definitive+Purchase+Agreements+to+Acquire+JumpstartRx+and+NueVistraMed%2C+Expanding+Telehealth+Footprint+and+Accelerating+Maxasome%E2%84%A2+Commercialization/26589760.html <p><em>Acquisitions bring immediate $135,000 in monthly recurring revenue prior to near-term scaling initiatives; Transaction structured as non-dilutive to $MAJI shareholders.</em></p> <p>ORLANDO, Fla., June 02, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCPK: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, today announced a major milestone in its corporate growth strategy with the execution of Definitive Purchase Agreements to acquire two prominent telehealth and clinical solutions platforms: <strong>JumpstartRx</strong> and <strong>NueVistraMed</strong>.</p> <p>The strategic acquisitions immediately inject $135,000 per month in baseline revenue into NexTel’s portfolio, with substantial near-term revenue expansion anticipated http://www.streetinsider.com/Press+Releases/NexTel+Medical+Corp.+Executes+Definitive+Purchase+Agreements+to+Acquire+JumpstartRx+and+NueVistraMed%2C+Expanding+Telehealth+Footprint+and+Accelerating+Maxasome%E2%84%A2+Commercialization/26589760.html Tue, 02 Jun 2026 11:23:00 -0400 MAJI O.09748628 http://www.streetinsider.com/Press+Releases/NexTel+Medical+Corp.+Executes+Definitive+Purchase+Agreements+to+Acquire+JumpstartRx+and+NueVistraMed%2C+Expanding+Telehealth+Footprint+and+Accelerating+Maxasome%E2%84%A2+Commercialization/26589760.html <p><em>Acquisitions bring immediate $135,000 in monthly recurring revenue prior to near-term scaling initiatives; Transaction structured as non-dilutive to $MAJI shareholders.</em></p> <p>ORLANDO, Fla., June 02, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCPK: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, today announced a major milestone in its corporate growth strategy with the execution of Definitive Purchase Agreements to acquire two prominent telehealth and clinical solutions platforms: <strong>JumpstartRx</strong> and <strong>NueVistraMed</strong>.</p> <p>The strategic acquisitions immediately inject $135,000 per month in baseline revenue into NexTel’s portfolio, with substantial near-term revenue expansion anticipated http://www.streetinsider.com/Press+Releases/NexTel+Medical+Corp.+Executes+Definitive+Purchase+Agreements+to+Acquire+JumpstartRx+and+NueVistraMed%2C+Expanding+Telehealth+Footprint+and+Accelerating+Maxasome%E2%84%A2+Commercialization/26589760.html Tue, 02 Jun 2026 11:23:00 -0400 MAJI O.09748628 http://www.streetinsider.com/Globe+Newswire/NexTel+Medical+Corp.+Executes+Definitive+Purchase+Agreements+to+Acquire+JumpstartRx+and+NueVistraMed%2C+Expanding+Telehealth+Footprint+and+Accelerating+Maxasome%E2%84%A2+Commercialization/26589760.html <p><em>Acquisitions bring immediate $135,000 in monthly recurring revenue prior to near-term scaling initiatives; Transaction structured as non-dilutive to $MAJI shareholders.</em></p> <p>ORLANDO, Fla., June 02, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCPK: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, today announced a major milestone in its corporate growth strategy with the execution of Definitive Purchase Agreements to acquire two prominent telehealth and clinical solutions platforms: <strong>JumpstartRx</strong> and <strong>NueVistraMed</strong>.</p> <p>The strategic acquisitions immediately inject $135,000 per month in baseline revenue into NexTel’s portfolio, with substantial near-term revenue expansion anticipated http://www.streetinsider.com/Globe+Newswire/NexTel+Medical+Corp.+Executes+Definitive+Purchase+Agreements+to+Acquire+JumpstartRx+and+NueVistraMed%2C+Expanding+Telehealth+Footprint+and+Accelerating+Maxasome%E2%84%A2+Commercialization/26589760.html Tue, 02 Jun 2026 11:23:00 -0400 MAJI O.09748628 http://www.streetinsider.com/Globe+Newswire/NexTel+Medical+Corp.+Executes+Definitive+Purchase+Agreements+to+Acquire+JumpstartRx+and+NueVistraMed%2C+Expanding+Telehealth+Footprint+and+Accelerating+Maxasome%E2%84%A2+Commercialization/26589760.html <p><em>Acquisitions bring immediate $135,000 in monthly recurring revenue prior to near-term scaling initiatives; Transaction structured as non-dilutive to $MAJI shareholders.</em></p> <p>ORLANDO, Fla., June 02, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCPK: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, today announced a major milestone in its corporate growth strategy with the execution of Definitive Purchase Agreements to acquire two prominent telehealth and clinical solutions platforms: <strong>JumpstartRx</strong> and <strong>NueVistraMed</strong>.</p> <p>The strategic acquisitions immediately inject $135,000 per month in baseline revenue into NexTel’s portfolio, with substantial near-term revenue expansion anticipated http://www.streetinsider.com/Globe+Newswire/NexTel+Medical+Corp.+Executes+Definitive+Purchase+Agreements+to+Acquire+JumpstartRx+and+NueVistraMed%2C+Expanding+Telehealth+Footprint+and+Accelerating+Maxasome%E2%84%A2+Commercialization/26589760.html Tue, 02 Jun 2026 11:23:00 -0400 MAJI O.09748628 http://www.streetinsider.com/Corporate+News/NexTel+Medical+begins+final+testing+phase+for+commercial+exosome+products/26467256.html <p>NexTel Medical Corp (OTCPK: MAJI) announced it has started the final stability testing phase for its commercial exosome products, marking its transition from clinical development to revenue generation.</p> <p>The biotechnology company reported that production batch samples tested negative for four common contaminants including E. coli, Salmonella, Pseudomonas aeruginosa, and Staphylococcus aureus using PCR technology. Stability vials are currently being monitored at room temperature and under refrigeration.</p> <p>The company stated that successful results at the 30-day mark would allow for immediate commercial launch of its additive-free exosome products.</p> <p>"We are now within 60 days of market entry," said Matt Dwyer, President of NexTel Medical http://www.streetinsider.com/Corporate+News/NexTel+Medical+begins+final+testing+phase+for+commercial+exosome+products/26467256.html Mon, 11 May 2026 11:53:26 -0400 MAJI O.09748628 http://www.streetinsider.com/Corporate+News/NexTel+Medical+begins+final+testing+phase+for+commercial+exosome+products/26467256.html <p>NexTel Medical Corp (OTCPK: MAJI) announced it has started the final stability testing phase for its commercial exosome products, marking its transition from clinical development to revenue generation.</p> <p>The biotechnology company reported that production batch samples tested negative for four common contaminants including E. coli, Salmonella, Pseudomonas aeruginosa, and Staphylococcus aureus using PCR technology. Stability vials are currently being monitored at room temperature and under refrigeration.</p> <p>The company stated that successful results at the 30-day mark would allow for immediate commercial launch of its additive-free exosome products.</p> <p>"We are now within 60 days of market entry," said Matt Dwyer, President of NexTel Medical http://www.streetinsider.com/Corporate+News/NexTel+Medical+begins+final+testing+phase+for+commercial+exosome+products/26467256.html Mon, 11 May 2026 11:53:26 -0400 MAJI O.09748628 http://www.streetinsider.com/Press+Releases/NexTel+Medical+Corp+Enters+Final+Stage+for+Commercial+Launch%3B+Sets+Sights+on+Revenue+Generation+and+OTCQB+Uplist/26467255.html <p>ORLANDO, Fla., May 11, 2026 (GLOBE NEWSWIRE) -- <strong>NexTel Medical Corp (f/k/a Exousia Pro, Inc.) (OTCPK: MAJI)</strong>, a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, is excited to announce the commencement of the final stability phase for its inaugural line of commercial exosome products. This milestone marks the transition from clinical development to active revenue generation, positioning the company for a transformative 2026.</p> <p><strong>Product Launch and Stability Testing</strong></p> <p>Last week, NexTel successfully initiated the stability testing phase, a critical precursor to market entry. Under the supervision of our Lab Director and Dr. Hausman, a http://www.streetinsider.com/Press+Releases/NexTel+Medical+Corp+Enters+Final+Stage+for+Commercial+Launch%3B+Sets+Sights+on+Revenue+Generation+and+OTCQB+Uplist/26467255.html Mon, 11 May 2026 11:53:00 -0400 MAJI O.09748628 http://www.streetinsider.com/Press+Releases/NexTel+Medical+Corp+Enters+Final+Stage+for+Commercial+Launch%3B+Sets+Sights+on+Revenue+Generation+and+OTCQB+Uplist/26467255.html <p>ORLANDO, Fla., May 11, 2026 (GLOBE NEWSWIRE) -- <strong>NexTel Medical Corp (f/k/a Exousia Pro, Inc.) (OTCPK: MAJI)</strong>, a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, is excited to announce the commencement of the final stability phase for its inaugural line of commercial exosome products. This milestone marks the transition from clinical development to active revenue generation, positioning the company for a transformative 2026.</p> <p><strong>Product Launch and Stability Testing</strong></p> <p>Last week, NexTel successfully initiated the stability testing phase, a critical precursor to market entry. Under the supervision of our Lab Director and Dr. Hausman, a http://www.streetinsider.com/Press+Releases/NexTel+Medical+Corp+Enters+Final+Stage+for+Commercial+Launch%3B+Sets+Sights+on+Revenue+Generation+and+OTCQB+Uplist/26467255.html Mon, 11 May 2026 11:53:00 -0400 MAJI O.09748628 http://www.streetinsider.com/Globe+Newswire/NexTel+Medical+Corp+Enters+Final+Stage+for+Commercial+Launch%3B+Sets+Sights+on+Revenue+Generation+and+OTCQB+Uplist/26467255.html <p>ORLANDO, Fla., May 11, 2026 (GLOBE NEWSWIRE) -- <strong>NexTel Medical Corp (f/k/a Exousia Pro, Inc.) (OTCPK: MAJI)</strong>, a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, is excited to announce the commencement of the final stability phase for its inaugural line of commercial exosome products. This milestone marks the transition from clinical development to active revenue generation, positioning the company for a transformative 2026.</p> <p><strong>Product Launch and Stability Testing</strong></p> <p>Last week, NexTel successfully initiated the stability testing phase, a critical precursor to market entry. Under the supervision of our Lab Director and Dr. Hausman, a http://www.streetinsider.com/Globe+Newswire/NexTel+Medical+Corp+Enters+Final+Stage+for+Commercial+Launch%3B+Sets+Sights+on+Revenue+Generation+and+OTCQB+Uplist/26467255.html Mon, 11 May 2026 11:53:00 -0400 MAJI O.09748628 http://www.streetinsider.com/Globe+Newswire/NexTel+Medical+Corp+Enters+Final+Stage+for+Commercial+Launch%3B+Sets+Sights+on+Revenue+Generation+and+OTCQB+Uplist/26467255.html <p>ORLANDO, Fla., May 11, 2026 (GLOBE NEWSWIRE) -- <strong>NexTel Medical Corp (f/k/a Exousia Pro, Inc.) (OTCPK: MAJI)</strong>, a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, is excited to announce the commencement of the final stability phase for its inaugural line of commercial exosome products. This milestone marks the transition from clinical development to active revenue generation, positioning the company for a transformative 2026.</p> <p><strong>Product Launch and Stability Testing</strong></p> <p>Last week, NexTel successfully initiated the stability testing phase, a critical precursor to market entry. Under the supervision of our Lab Director and Dr. Hausman, a http://www.streetinsider.com/Globe+Newswire/NexTel+Medical+Corp+Enters+Final+Stage+for+Commercial+Launch%3B+Sets+Sights+on+Revenue+Generation+and+OTCQB+Uplist/26467255.html Mon, 11 May 2026 11:53:00 -0400 MAJI O.09748628 http://www.streetinsider.com/Corporate+News/NexTel+Medical+begins+distribution+of+cancer+screening+test+kits/26281579.html <p>NexTel Medical Corp (OTCPK: MAJI) announced it will begin distributing test kits this week to collect control samples for its NANOG DNA cancer screening test. The company said these samples will serve as benchmarks for validation against 100 test samples as part of its commercial launch preparation.</p> <p>The biotechnology company, formerly known as Exousia Pro Inc., said it is expanding its testing protocols to include additional cancer types beyond its initial patent scope. NexTel received a patent for the test based on a limited sample set and is now working to demonstrate broader applicability.</p> <p>The NANOG DNA test is designed as a http://www.streetinsider.com/Corporate+News/NexTel+Medical+begins+distribution+of+cancer+screening+test+kits/26281579.html Tue, 07 Apr 2026 13:08:24 -0400 MAJI O.09748628